Clinical Trial Update: Safety and Efficacy of LibiGel® for Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update on LibiGel for hypoactive sexual desire disorder in postmenopausal women reports safety and efficacy results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypoactive Sexual Desire Disorder

Drugs mentioned

• LibiGel (testosterone topical gel)

Snippet

Sponsor: BioSante Pharmaceuticals | Conditions: Hypoactive Sexual Desire Disorder | Phase 3 | Status: COMPLETED